Carmignac Gestion Has $148.67 Million Holdings in Lantheus Holdings, Inc. $LNTH

Carmignac Gestion increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,340,100 shares of the medical equipment provider’s stock after purchasing an additional 12,100 shares during the quarter. Lantheus accounts for approximately 1.9% of Carmignac Gestion’s investment portfolio, making the stock its 16th largest position. Carmignac Gestion owned 2.05% of Lantheus worth $148,671,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. California State Teachers Retirement System raised its position in shares of Lantheus by 10,684.5% in the 2nd quarter. California State Teachers Retirement System now owns 8,434,214 shares of the medical equipment provider’s stock valued at $935,692,000 after buying an additional 8,356,007 shares in the last quarter. Jupiter Topco LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth approximately $575,628,000. Farallon Capital Management LLC boosted its position in shares of Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after acquiring an additional 1,950,252 shares in the last quarter. Norges Bank acquired a new stake in shares of Lantheus during the 4th quarter worth approximately $76,197,000. Finally, Freestone Grove Partners LP increased its stake in Lantheus by 4,114.8% in the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after acquiring an additional 594,088 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LNTH has been the subject of several recent analyst reports. Leerink Partners set a $102.50 target price on Lantheus in a research note on Monday, August 3rd. William Blair set a $102.50 price target on Lantheus in a research note on Monday, August 3rd. Citizens Jmp reissued a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a report on Monday, June 29th. Mizuho dropped their price objective on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Wednesday, July 29th. Finally, Brookline Capital Markets lowered Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Four analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, Lantheus currently has an average rating of “Hold” and a consensus price target of $108.11.

Lantheus Price Performance

LNTH stock traded down $0.53 during trading on Tuesday, reaching $100.44. 1,088,870 shares of the company were exchanged, compared to its average volume of 1,099,459. The company has a 50-day moving average of $102.94 and a two-hundred day moving average of $93.12. The company has a market capitalization of $6.56 billion, a price-to-earnings ratio of 24.26 and a beta of -0.03. Lantheus Holdings, Inc. has a twelve month low of $49.67 and a twelve month high of $111.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The firm had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company’s quarterly revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the business posted $1.57 earnings per share. As a group, equities analysts predict that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.